Problem:
If you were a policy analyst, what would you recommend and to whom? What policy changes might be needed to support government-sponsored initiatives related to comparative effectiveness research (CER) and evidence-based medicine? If you were an insurer, how would you respond to the recommendation that insurers facilitate CER research? What forms might such facilitation take?